Public Policy Priorities
For more than 30 years, the Celiac Disease Foundation and our national network of advocates have worked diligently for federal recognition of celiac disease as one of the world’s most prevalent, and least diagnosed, genetic autoimmune diseases. We continue to educate our elected officials on the impact of celiac disease, and to emphasize the need for gluten-free labeling standards and funding of celiac disease research and education programs. Together, we must work to make our voices heard to elevate celiac disease on the nation’s healthcare agenda. The Foundation is committed to working with the United States Congress, federal government agencies, and state legislatures and agencies to improve the lives of the more than three million Americans affected by celiac disease.
Increase funding for the National Institutes of Health (NIH) for the study of celiac disease
The federal government is the biggest provider of medical research funding, but up until recently federal funding for celiac disease has been limited. Beginning with CEO Marilyn G. Geller’s testimony before the House Appropriations Subcommittee in April of 2019, the Celiac Disease Foundation has worked to secure FY2020 and FY2021 Appropriations report language directing the NIH to devote sufficient, focused research to the study of celiac disease. Funding is needed to determine causation, find treatment alternatives to a gluten-free diet, and ultimately, cure celiac disease. On March 18 and 19, 2021, the National Institutes of Health will convene experts from around the country to a virtual workshop entitled “Accelerating Progress in Celiac Disease”. Please encourage your representatives to support this path forward to research focused on finding relief for those afflicted by celiac disease.
Include celiac disease in the Congressionally Directed Medical Research Programs (CDRMP)
The CDRMP supports medical research projects that are relevant to enhancing the health, care, and well-being of military families, and the American public. While celiac disease is a disqualifying condition for military service, its prevalence has increased among service members, veterans, and their family members. The Celiac Disease Foundation through its membership in the Defense Health Research Consortium, strives to protect and preserve funding for the Congressionally Directed Medical Research Programs (CDMRP). Research will benefit those suffering from celiac disease by generating strategies to prevent the disease and providing critical guidance on mitigation efforts affecting readiness.
Include celiac disease in the Diseases and Conditions A-Z index at the Centers for Disease Control and Prevention (CDC)
The CDC Diseases and Conditions A-Z index lists topics of frequent inquiry or critical importance to the CDC’s public health mission. Celiac disease, as one of the world’s most common genetic autoimmune diseases, must be listed.
Access to Care
Protect chronic disease patients from discrimination and bolster patient protections
As Congress and the Administration contemplate changes to the US healthcare system, it is critical for celiac disease patients that pre-existing condition discrimination continues to be prohibited and that individuals be able to equitably access comprehensive healthcare coverage regardless of their health status, diagnosis, and related factors.
Extend Medicare and Medicaid coverage for Medical Nutrition Therapy to beneficiaries with celiac disease
Lack of adherence to a gluten-free diet significantly affects mortality for those with celiac disease. Newly diagnosed patients require nutritional therapy provided by a registered dietitian or nutrition professional to navigate the gluten-free diet.
Require disclosure of gluten in medications
Labeling of the presence of gluten in medications allows consumers to make safe, informed purchases of needed medicines.
FDA funding for enforcement of the Gluten-Free Labeling Rule
The 2014 FDA Gluten-Free Labeling Rule was a tremendous achievement for celiac disease patients as it requires that a gluten-free label on a packaged food product ensure that the product contains less than 20 parts per million of gluten, which is the safe threshold of gluten consumption for those with celiac disease. The FDA requires sufficient resources to maintain its ongoing compliance program.